TWAPF Stock Chart & Stats
$25.33
$0.00(0.00%)
At close: 4:00 PM EST
$25.33
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$20.72 - $28.05
Previous CloseN/A
Volume1.00
Average Volume (3M)3.00
Market Cap
$1.11B
Enterprise Value$375.50K
Total Cash (Recent Filing)$42.23B
Total Debt (Recent Filing)$229.93B
Price to Earnings (P/E)21.0
Beta0.46
Next Earnings
Nov 16, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend Yield3.02%
Share Statistics
EPS (TTM)167.96
Shares Outstanding51,516,000
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.11
Price to Sales (P/S)0.72
P/FCF Ratio24.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$36.47Price Target Upside43.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.92
Revenue Forecast (FY)$1.92B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginContinued revenue expansion with a stable gross margin indicates that Towa is retaining broadly consistent production economics while growing its business. This combination supports operating scale, helps fund product development, and provides a more durable base for recovery if profitability improves.
Broad Generic Portfolio And In-House ManufacturingA broad portfolio across therapeutic areas can diversify product-level exposure and increase relevance to wholesalers, hospitals, and pharmacies. In-house manufacturing and scale may also support cost control, supply management, and the ability to refresh products as patents expire.
Structural Generic Drug DemandThe company operates in a structurally relevant segment because generic medicines provide lower-cost alternatives after branded-drug patents expire. That role can support recurring prescription demand and gives Towa a continuing market opportunity as healthcare providers seek cost-effective treatment.
Bears Say
Sharp Profitability CompressionMaterially lower net and EBIT margins show that revenue growth is currently translating into much less profit than in prior years. If this compression persists, Towa will have fewer internally generated resources for launches, manufacturing investment, debt reduction, and shareholder returns.
Elevated And Rising LeverageHigher debt alongside weaker profitability increases the importance of disciplined cash allocation and reduces financial flexibility. Greater leverage can constrain investment choices and leave the company less able to absorb prolonged margin pressure while maintaining product and operating commitments.
Thin And Volatile Free Cash FlowThin free cash flow and weak conversion from reported earnings indicate limited surplus cash after investment needs. The history of volatility, including negative free-cash-flow years, makes it harder to sustain debt reduction, fund growth internally, and reliably support cash returns.
Towa Pharmaceutical Co News
TWAPF FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was $20.72 and its highest was $28.05 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is $1.11B.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 16, 2026 which is in 66 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported $0.732 earnings per share for the quarter.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd pays a Semiannually dividend of $0.259 which represents an annual dividend yield of 3.02%. See more information on Towa Pharmaceutical Co Ltd dividends here
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate is 0.66.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of $0.732 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in TWAPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
TWAPF Stock 12 Month Forecast
Average Price Target
$36.47
▲(43.97% Upside)
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Ownership Overview
―
Insiders
6.44% Mutual Funds
― Other Institutional Investors
89.26% Public Companies and
Individual Investors